Spondyloarthritis & psoriatic arthritis
Achieving Axial Spondyloarthritis Disease Activity Score Inactive Disease Status in Axial Spondyloarthritis in Clinical Trials: A Systematic Review and Metaanalysis
Pooled result · Pooled proportion achieving ID (ASDAS <1.3)Result — go to the resultodds 0.30 95% CI 0.17–0.51Authors' conclusion
This study demonstrates that attainment of ASDAS-ID in axSpA clinical trials is consistently low, reflecting the stringency of this remission threshold within trial designs.
Study context
- Population
- Patients with radiographic or nonradiographic axial spondyloarthritis (axSpA) treated with biologic therapies (tumor necrosis factor inhibitors (TNFi), IL17i) or targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) such as Janus kinase inhibitors (JAKi); studies from inception through August 2025
- Participants
- 6,171 patients19 randomized controlled trials (RCTs)
- Comparison
- ASDAS-ID vs ASDAS-LDA attainment
- Outcome
- Proportion of patients with axSpA achieving ID compared to LDA
Methodological detailsRCTs and open-label extension studies, Cochrane risk of bias (ROB) tool, 2 independent reviewers, pooled ORs with 95% CIs, I 2 heterogeneity, 41 unique studies included; 22 open-label extension (OLE) studies, several from the same parent RCT
- RCTs and open-label extension studies
- Cochrane ROB tool
- 2 independent reviewers
- Pooled ORs with 95% CIs
- I 2 heterogeneity
- 41 unique studies included; 22 OLE studies, several from the same parent RCT
Pooled result
Pooled proportion achieving ID (ASDAS <1.3) · 12-24 weeks
odds
0.30
95% CI 0.17–0.51
By group
Treatment
0.24
pooled proportion · 95% CI 0.18–0.31
As reported in the abstract
Further pooled results
| Outcome | Values |
|---|---|
| Pooled proportion achieving ID, OLE phases · weeks 48-52 | OLE pooled proportion 0.22 (95% CI 0.17–0.28) |
| Pooled proportion achieving ID, OLE phases · weeks 96-156 | OLE pooled proportion 0.35 (95% CI 0.25–0.43) |
Original publication
Achieving Axial Spondyloarthritis Disease Activity Score Inactive Disease Status in Axial Spondyloarthritis in Clinical Trials: A Systematic Review and Metaanalysis. J Rheumatol. Published 15 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →